8-K: Foghorn Therapeutics Appoints Interim CFO Jeff Sacher

Foghorn Therapeutics Inc. announced the appointment of Jeff Sacher as interim Chief Financial Officer and Treasurer, effective immediately.

Summary

• Foghorn Therapeutics Inc. appointed Jeff Sacher as Treasurer and interim Chief Financial Officer (CFO), effective December 3, 2025.
• The company is actively continuing its search for a permanent CFO.
• Mr. Sacher, age 60, is a CFO at Danforth Advisors, LLC, a firm that already provides strategic and financial consulting services to Foghorn Therapeutics.
• Foghorn Therapeutics will compensate Danforth Advisors, LLC for Mr. Sacher's services at an agreed hourly rate and will reimburse expenses.
• Mr. Sacher brings 35 years of experience from the biotechnology and investment banking industries, having served as a CFO at Danforth since May 2022 and previously as a senior investment banker.
• He holds an M.B.A. from the Kellogg School of Management and a B.A. in biology from Cornell University.

Sentiment

Score: 6

Explanation: The appointment of an experienced interim CFO provides stability during a transition period, which is a neutral to slightly positive development. However, the interim nature and ongoing search for a permanent CFO prevent a higher score.

Positives

• Appointment of an experienced interim CFO with 35 years in biotechnology and investment banking ensures continuity in financial leadership.
• Leveraging an existing consulting relationship with Danforth Advisors, LLC for interim CFO services may streamline the transition and reduce immediate onboarding complexities.

Negatives

• The appointment is interim, indicating a lack of a permanent CFO, which could suggest ongoing leadership transition or search challenges.

Risks

• The interim nature of the CFO role could lead to uncertainty regarding long-term financial strategy and leadership stability until a permanent replacement is found.
• Reliance on a consulting firm for a key executive role might introduce different dynamics compared to a full-time, in-house executive.

Future Outlook

The company is continuing its search for a permanent Chief Financial Officer, indicating an ongoing process to solidify its long-term financial leadership.

Industry Context

In the biotechnology sector, strong financial leadership is crucial for managing R&D investments, clinical trial funding, and potential commercialization efforts. An interim CFO appointment, while providing immediate stability, highlights the ongoing challenge of securing permanent executive talent in a competitive industry.

Management Changes

Related Party Transactions

• The company has an existing agreement with Danforth Advisors, LLC, where Mr. Sacher is a CFO. The company will pay Danforth an agreed hourly rate for Mr. Sacher's interim CFO services and reimburse expenses.

Stakeholder Impact

• Shareholders: Provides continuity in financial oversight during a transition, potentially reducing uncertainty.
• Employees: Ensures stable financial leadership, which can contribute to overall company stability.
• Creditors/Investors: An experienced interim CFO can maintain confidence in financial reporting and management during the search for a permanent executive.

Next Steps

• Continue the search for a permanent Chief Financial Officer.

Key Dates

Keywords

Foghorn Therapeutics, FHTX, Interim CFO, Chief Financial Officer, Treasurer, Management Change, Biotechnology, Danforth Advisors, SEC Filing, Corporate Governance